RSV is an important cause of severe respiratory disease in older adults and is associated with a high morbidity and mortality. After RSV natural infection, there is only a relatively short duration of immunity. Currently, there is no licensed vaccine to prevent RSV infection and no specific effective treatments for RSV exist, consisting primarily of supportive care. The only available prophylactic measure is an RSV fusion glycoprotein (F)-specific monoclonal, which is limited to use in high-risk infants and requires costly, monthly injections. Therefore, there is an important unmet medical need to develop an effective vaccine to boost the immune response sufficiently to protect older adults against RSV disease.
To qualify for this study, you must be:
- 60 years of age or older
- Medically healthy, or stable with preexisting condition.
- Other criteria may apply during screening
Compensation for time and travel will be available to enrolled subjects
To learn more about this trial and to find out if you qualify, please call 402-934-0044 or complete the form on our contact page.